Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatic Disease & Reproductive Health

Jason Liebowitz, MD, FACR  |  November 21, 2023

Medication Guides & More

With regard to medication recommendations, the guides developed by Dr. Clowse and colleagues include information on which treatments are safe, or not safe, in pregnancy. Azathioprine tends to be a go-to medication that is compatible with pregnancy, and all patients with SLE should be on hydroxychloroquine, which is known to reduce lupus disease activity and adverse outcomes in pregnancy.4-7

If a change in medication is made, it may sometimes be reasonable for a patient to wait three to nine months after this change before conceiving to ensure the new medication regimen remains effective.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Clowse encourages providers to have a plan for other issues that may arise. Examples include appropriate anticoagulation for patients with antiphospholipid syndrome, monitoring for congenital heart block in patients with anti-SSA antibodies, avoidance of ACEi/ARB medications during pregnancy and plans for how to manage pain during pregnancy.


Jason Liebowitz, MDJason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

 References

  1. Venne K, Scott S, Bernatsky S, Vinet E. Induced abortions in women with systemic lupus erythematosus. Lupus. 2021;30(3):484–488.
  2. Dobbs, State Health Officer of the Mississippi Department of Health, et al. v. Jackson Women’s Health Organization et al. U.S. Supreme Court. 2022 Jun 24.
  3. Bermas BL, Blanco I, Blazer AD, et al. Overturning Roe v. Wade: Toppling the practice of rheumatology. Arthritis Rheumatol. 2022 Dec;74(12):1865–1867.
  4. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020;72(4):461–488.
  5. Sperber K, Hom C, Chao CP, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J. 2009 May 13;7:9.
  6. Clowse MEB, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640–3647.
  7. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003 Nov;48(11):3207–3211.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2023

Related Articles

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?

    December 6, 2022

    How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?

    Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

    November 16, 2016

    The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

    Challenges in Reproductive Health in Rheumatic Disease

    July 11, 2022

    In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences